- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05478538
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cancer is a leading cause of death and despite many new drugs, a major diagnostic challenge remains knowing which drug will work best for a patient. A new class of drugs called immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, current diagnostic methods (e.g. PDL1, MSI and TMB) do not accurately predict which patients will respond.
Elephas is developing a diagnostic platform using small 3D Live Tumor Fragments (LTFs) from participants for accurate prediction of drug response with a focus on ICIs such as Pembrolizumab (Keytruda). These LTFs contain both tumor cells and infiltrating immune cells, which are critical in determining response to ICIs and other immunotherapies.
In this observational clinical trial, 200 Non-Small Cell Lung Cancer (NSCLC) participants will be recruited and their actual clinical response to ICIs (using RECIST 1.1) will be compared to the platform's predictive Artificial Intelligence (AI) score that is based on RNA, clinical data, and 3D microscopy images. The sensitivity and specificity of the platform's score will be determined and compared to current diagnostic methods for ICIs like PDL1, MSI, and TMB.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Catarina Costa
- Phone Number: 609-955-4927
- Email: ClinicalTrials@elephas.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Not yet recruiting
- UCLA Medical Center
-
Contact:
- Saima Chaabane
- Email: SChaabane@mednet.ucla.edu
-
Principal Investigator:
- Fereidoun Abtin, MD
-
-
Maryland
-
Frederick, Maryland, United States, 21702
- Not yet recruiting
- James M Stockman Cancer Institute
-
Contact:
- Ingrid Halvorson
- Email: IHalvorson@Frederick.health
-
Principal Investigator:
- Heather Chalfin, MD
-
-
New York
-
Shirley, New York, United States, 11967
- Not yet recruiting
- New York Cancer & Blood Specialists
-
Principal Investigator:
- Richard Zuniga, MD
-
Contact:
- Laura Parisi
- Email: lparisi@nycancer.com
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Terminated
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Terminated
- Gabrail Cancer Center
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Recruiting
- JPS Health Network
-
Contact:
- April Bell
- Email: ABell01@jpshealth.org
-
Principal Investigator:
- Paras Patel, MD
-
Temple, Texas, United States, 76508
- Recruiting
- Baylor Scott & White Research Institute
-
Contact:
- Lorie A Fares
- Phone Number: 254-724-2841
- Email: Lorie.Fares@BSWHealth.org
-
Contact:
- Andrea G Mosko
- Phone Number: 254-724-2841
- Email: Andrea.Mosko@BSWHealth.org
-
Principal Investigator:
- Alan Gowan, DO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Subject Inclusion Criteria
- Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
- Age ≥ 18 years at the time of consent.
Subjects suspected of or diagnosed with Stage IV/metastatic NSCLC and meet one of the following criteria:
- Subjects who are undiagnosed, have undergone imaging and are suspected to have Stage IV lung cancer.
- Subjects with a previous Stage I, II, or III diagnosis of NSCLC, who are being re-biopsied due to suspected progression to metastatic disease.
- Subjects who have a newly confirmed diagnosis of Stage IV NSCLC, have undergone a SOC biopsy procedure and will undergo a separate procedure for the purposes of this study prior to starting first line treatment.
- Subjects who have a previous Stage IV/metastatic NSCLC diagnosis and have already received first line treatment.
- Subjects must be clinically able, at investigator discretion, to undergo additional CNB or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
- Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.
Subject Exclusion Criteria
- Any patient for whom an extra biopsy might pose a clinical risk based on the discretion of the clinician.
- Any mental impairment that would render the patient unable to understand his/her participation in the study would disqualify the patient from consenting and participating.
- Subjects with an auto-immune disease that would render them ineligible for immune- oncology treatment.
- Immunocompromised subjects, and subjects known to be HIV positive and currently receiving antiretroviral therapy. NOTE: Patients known to be HIV positive, but without clinician evidence of an immunocompromised state, are eligible for this trial.
- Subjects who are enrolled or plan to be enrolled in a blinded oncology treatment trial are not eligible.
- Subjects who are pregnant are not eligible.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Stage IV or metastatic Non Small Cell Lung Cancer (NSCLC)
Subjects suspected of or diagnosed with Stage IV NSCLC and meet one of the following criteria:
|
Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy.
These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and Specificity of Cybrid Score for Predicting In-Vivo Clinical Response to Immune Checkpoint Inhibitors
Time Frame: 3 years
|
The ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform will be determined using in-vivo RECIST 1.1 as the reference method.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the Area Under the Receiver Operating Characteristic Curve (AUC) of Cybrid Score and Compare to the AUCs of Current FDA Approved Predictive Biomarkers PD-L1 and Tumor Mutation Burden (TMB)
Time Frame: 3 years
|
The AUC of Cybrid Score will be established with a clinically meaningful confidence interval and compared to the AUCs of established FDA approved biomarkers for predicting clinical response to ICIs.
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Fred Hausheer, MD, FACP, Elephas
Publications and helpful links
General Publications
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
- Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Erratum In: Lancet Oncol. 2019 May;20(5):e242.
- Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Cui P, Huang D, Huang Z, Wu Z, Hu Y. Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Front Oncol. 2021 Apr 16;11:562315. doi: 10.3389/fonc.2021.562315. eCollection 2021.
- Cherukuri AR, Lubner MG, Zea R, Hinshaw JL, Lubner SJ, Matkowskyj KA, Foltz ML, Pickhardt PJ. Tissue sampling in the era of precision medicine: comparison of percutaneous biopsies performed for clinical trials or tumor genomics versus routine clinical care. Abdom Radiol (NY). 2019 Jun;44(6):2074-2080. doi: 10.1007/s00261-018-1702-1.
- Basumallik N, Agarwal M. Small Cell Lung Cancer. 2023 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK482458/
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ELEP-2022-CYBRID-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Xinqiao Hospital of ChongqingCompleted
-
Seoul St. Mary's HospitalBoehringer IngelheimActive, not recruiting
-
Taipei Veterans General Hospital, TaiwanNational Taiwan University Hospital; China Medical University Hospital; Tri-Service... and other collaboratorsUnknown
-
AstraZenecaCompletedNSCLCSweden, Bulgaria, Mexico, Russian Federation, Turkey, United Kingdom, Philippines, Malaysia, Germany, Hungary, Latvia, Lithuania, Poland, Romania, Netherlands, Norway, Argentina, Australia, Canada, Slovakia, Greece, Taiwan, Thailand, ... and more
Clinical Trials on Core Needle or Forceps Biopsy
-
ElephasHoosier Cancer Research NetworkRecruitingClear Cell Renal Cell Carcinoma | Colorectal Cancer | Non Small Cell Lung Cancer | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Cutaneous MelanomaUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
Shandong Cancer Hospital and InstituteUnknown
-
Philips HealthcareWithdrawnProstate CancerUnited States
-
Ourotech, Inc.Barts & The London NHS TrustRecruitingTriple Negative Breast Cancer | Triple Negative Breast NeoplasmsUnited Kingdom
-
Rna Diagnostics Inc.RecruitingBreast Neoplasm FemaleGermany, United States, Canada, France, Italy, Spain, Poland
-
M.D. Anderson Cancer CenterCompletedMalignant Neoplasm of Pancreas | Solid Pancreatic Mass LesionsUnited States
-
San Antonio Uniformed Services Health Education...Not yet recruitingCryobiopsy of Peripheral Lymph NodesUnited States
-
NeoDynamics ABRecruitingBreast CancerUnited Kingdom
-
Shandong Cancer Hospital and InstituteUnknownBreast Cancer | Sentinel Lymph NodeChina